

John B A G Haanen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/423437/john-b-a-g-haanen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354
papers

48,826
citations

74
h-index

220
g-index

408
ext. papers

60,101
ext. citations

10.4
avg, IF

7.15
L-index

#	Paper	IF	Citations
354	Developments in Solid Tumours 2022 , 105-108		
353	Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.. <i>European Urology Open Science</i> , 2022 , 35, 54-58	0.9	2
352	Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022 , 150, 317-326	7.5	1
351	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	16
350	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101806	2.2	1
349	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.. <i>European Journal of Cancer</i> , 2022 , 167, 70-80	7.5	2
348	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 274.e1-274.e16 ²	2.2	1
347	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.. <i>Nature Communications</i> , 2021 , 12, 7348	17.4	8
346	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	2
345	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021 , 31, 58-66	3.3	0
344	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
343	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8 T cells. <i>Cell Reports</i> , 2021 , 37, 110013	10.6	4
342	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1681-1691	21.7	22
341	Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology, The</i> , 2021 , 22, e550-e561	21.7	3
340	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. <i>ESMO Open</i> , 2021 , 6, 100320	6	0
339	The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.. <i>ESMO Open</i> , 2021 , 7, 100374	6	6
338	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2021 ,	7.5	2

337	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2021 ,	7.5	6
336	Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. <i>BJU International</i> , 2021 ,	5.6	1
335	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021 , 43, 539-540.	0.9	1
334	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 82-89	2.7	1
333	The power to "di-sc-seq-t". <i>Cancer Cell</i> , 2021 , 39, 299-301	24.3	
332	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 3123-3135	7.4	0
331	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021 , 6, 100058	6	18
330	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial. <i>Annals of Surgery</i> , 2021 , 274, 383-389	7.8	7
329	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21523-e21523	2.2	
328	Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4548-4548	2.2	1
327	Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4574-4574	2.2	5
326	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18641-e18641 ^{2.2}		
325	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 641-648	8	10
324	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4547-4547 ^{2.2}		
323	Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4573-4573	2.2	0
322	IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11582-TPS11582	2.2	0
321	BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9558-9558	2.2	
320	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9544-9544	2.2	

319	Dutch advanced melanoma care in times of COVID-19.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21502-e21502	0
318	Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2661-TPS2661	2.2 0
317	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4597-TPS4597	2.2 2
316	Efficacy of checkpoint inhibition in advanced acral melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21527-e21527	2.2
315	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9506-9506	2.2 29
314	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6 3
313	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6 1
312	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021 , 32, 766-777	10.3 3
311	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors 2021 , 9,	2
310	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 36-48	2.4 61
309	Cellular Therapy and Cytokine Treatments for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 129-144	3.1 4
308	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1227-1237	7.4 7
307	Immuun- en targeted therapie 2021 , 217-236	
306	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,	20
305	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021 , 124, 1222-1230	8.7 4
304	An open-label phase II study comparing two doses of MK-6482 for the treatment of advanced renal cell carcinoma (RCC) following progression on prior systemic therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS369-TPS369	2.2
303	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. <i>European Journal of Cancer</i> , 2021 , 144, 242-251	7.5 6
302	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021 , 27, 568-569	50.5 30

301	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021 , 15, 510-519	8.8	4
300	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021 , 27, 256-263	50.5	52
299	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021 , 21, 323	4.8	5
298	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021 , 27, 1250-1261	50.5	31
297	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021 , 6, 100199	6	9
296	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 1031-1038	3.6	0
295	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1
294	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021 , 154, 111-119	7.5	3
293	Survival of stage IV melanoma in Belgium and the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	1
292	Adjuvant treatment for melanoma in clinical practice - Trial versus reality. <i>European Journal of Cancer</i> , 2021 , 158, 234-245	7.5	1
291	LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. <i>Annals of Oncology</i> , 2021 , 32, S1337	10.3	4
290	Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry. <i>European Journal of Cancer</i> , 2021 , 156, 24-34	7.5	6
289	Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. <i>European Journal of Cancer</i> , 2021 , 157, 225-237	7.5	1
288	T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN- γ /TNF- α or IL-2 production. <i>Oncolimmunology</i> , 2021 , 10, 1860482	7.2	5
287	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
286	[F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 49, 2010	8.8	0
285	LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. <i>Annals of Oncology</i> , 2020 , 31, S1169	10.3	7
284	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1119-1136	8.9	51

283	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020 , 12,	6.6	6
282	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020 , 147, 3461-3470	7.5	11
281	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy 2020 , 8,		45
280	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Oncology</i> , 2020 , 9, 1738814	7.2	6
279	Deferred Cytoablative Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020 , 3, 168-173	6.7	9
278	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020 , 26, 566-576	50.5	262
277	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020 , 12,	6.6	4
276	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials 2020 ,		6
275	Immunotherapie van kanker 2020 , 191-201		
274	Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 703-703	2.2	
273	Cancer management in the era of immunotherapy: much more than meets the eye. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 64, 141-142	1.4	1
272	Prognostic and predictive role of the tumor immune landscape. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 64, 143-151	1.4	1
271	Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma 2020 , 1109-1140		
270	Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 498-506	4.5	5
269	Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). <i>Melanoma Research</i> , 2020 , 30, 252-260	3.3	20
268	A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. <i>International Journal of Cancer</i> , 2020 , 147, 1143-1151	7.5	5
267	Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e15-e20	8.9	2
266	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy 2020 , 8,		13

265	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1435-1448	10.3	49
264	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020 , 5, e000945		2
263	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020 , 141, 171-184	7.5	37
262	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. <i>European Journal of Cancer</i> , 2020 , 137, 127-135	7.5	7
261	Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness. <i>BMC Cancer</i> , 2020 , 20, 712	4.8	6
260	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020 , 12,	6.6	7
259	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up 2020 , 8,		19
258	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1449-1461	10.3	19
257	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020 , 38, 500-515.e3	24.3	75
256	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020 , 26, 1733-1741	50.5	85
255	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020 , 43, 256-264	5	4
254	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 529-532	3.6	
253	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020 , 26, 2268-2274	12.9	61
252	The Outcome of TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020 , 26, 4289-4301	12.9	17
251	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32
250	Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1545-1552	8.9	13
249	Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. <i>Oncotmunology</i> , 2019 , 8, e1648170	7.2	19
248	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260

247	Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). <i>European Urology</i> , 2019 , 76, 437-440	10.2	16
246	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , 2019 , 20, 948-960	21.7	186
245	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
244	Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. <i>Journal of Biotechnology</i> , 2019 , 306S, 100007	3.7	8
243	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019 , 25, 920-928	50.5	302
242	Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. <i>Annals of Oncology</i> , 2019 , 30, 998-1004	10.3	198
241	Glutaminy cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. <i>Nature Medicine</i> , 2019 , 25, 612-619	50.5	77
240	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. <i>Oncotarget</i> , 2019 , 8, 1558664	7.2	
239	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019 , 30, 1154-1161	10.3	93
238	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1103-1115	59.2	1069
237	Cryoablation and immunotherapy: an overview of evidence on its synergy. <i>Insights Into Imaging</i> , 2019 , 10, 53	5.6	38
236	A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). <i>Future Oncology</i> , 2019 , 15, 2203-2209	3.6	11
235	Transgenerational transfer of gene-modified T cells 2019 , 7, 186		2
234	Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019 , 11,	6.6	16
233	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5	19
232	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019 , 4, e000472	6	15
231	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019 , 123, 58-71	7.5	15
230	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 101-101	2.2	59

229	Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2575-2575	2.2	12
228	Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9587-9587	2.2	5
227	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 544-544	2.2	11
226	Cytokines (IL-2, IFN GM-CSF etc) Melanoma 2019 , 1-31		
225	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 787-798	7.4	1
224	How I treat MSI cancers with advanced disease. <i>ESMO Open</i> , 2019 , 4, e000511	6	13
223	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019 , 11,	6.6	18
222	Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology. <i>Otology and Neurotology</i> , 2019 , 40, e674-e678	2.6	7
221	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. <i>Cell</i> , 2019 , 176, 775-789.e18	56.2	368
220	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 319-329	7.4	7
219	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019 , 7, 77-85	12.5	61
218	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2019 , 7, 6-11	12.5	61
217	Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 449-461	5.1	139
216	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 503-515	7.4	18
215	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 164-170	13.4	180
214	Characterisation of rare haematological immune-related toxicities. <i>Lancet Haematology,the</i> , 2019 , 6, e10-e11	14.6	
213	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. <i>Nature Medicine</i> , 2019 , 25, 89-94	50.5	246
212	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018 , 29, 579-588	2.4	7

211	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018 , 29, 572-578	2.4	8
210	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018 , 3, e000278	6	136
209	Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. <i>Melanoma Research</i> , 2018 , 28, 126-133	3.3	20
208	Questions asked in the everyday practice: immune checkpoint inhibitors. <i>ESMO Open</i> , 2018 , 3, e000395	6	1
207	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. <i>Cell</i> , 2018 , 174, 1586-1598.e12	56.2	348
206	Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N161MC, NCT03003637).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18020-e18020	2.2	2
205	A phase 2, single-arm trial of neoadjuvant axitinib plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4604-TPS4604	2.2	2
204	Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS9602-TPS9602	2.2	1
203	Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4572-4572	2.2	
202	Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9585-9585	2.2	
201	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 303-317	7.1	64
200	Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. <i>Journal of Immunotherapy</i> , 2018 , 41, 413-425	5	8
199	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018 , 3, e000422	6	30
198	NKG2A, a New Kid on the Immune Checkpoint Block. <i>Cell</i> , 2018 , 175, 1720-1722	56.2	51
197	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nature Medicine</i> , 2018 , 24, 1655-1661	50.5	351
196	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018 , 3, e000423	6	17
195	Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option 2018 , 6, 102		85
194	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. <i>BMC Cancer</i> , 2018 , 18, 895	4.8	9

193	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018 , 28, 326-332	3.3	5
192	Cytoreductive nephrectomy in metastatic renal cancer - less is more. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 595-596	19.4	3
191	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. <i>Cancer Immunology Research</i> , 2017 , 5, 170-179	12.5	19
190	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , 2017 , 20, 205-215	10.6	52
189	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
188	HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1163-1173	7.4	10
187	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
186	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 501-508	13.4	17
185	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017 , 72, 156-165	7.5	53
184	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. <i>BMC Cancer</i> , 2017 , 17, 649	4.8	9
183	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
182	Converting Cold into Hot Tumors by Combining Immunotherapies. <i>Cell</i> , 2017 , 170, 1055-1056	56.2	138
181	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. <i>Annals of Oncology</i> , 2017 , 28, 862-867	10.3	9
180	Fixed Dosing of Monoclonal Antibodies in Oncology. <i>Oncologist</i> , 2017 , 22, 1212-1221	5.7	82
179	Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. <i>Urology</i> , 2017 , 109, 127-133	1.6	4
178	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv119-iv142	10.3	1100
177	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	178
176	Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 125-128	2.9	12

175	Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017 , 3, 188-192	1.6	15
174	Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). <i>Annals of Oncology</i> , 2017 , 28, v622	10.3	14
173	Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038 2017 ,		2
172	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) 2017 ,		26
171	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
170	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9539-9539	2.2	4
169	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9586-9586	2.2	16
168	Immune checkpoint inhibition-related colitis: Correlation between ulcers and need for infliximab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21062-e21062	2.2	1
167	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4594-TPS4594	2.2	12
166	Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 514-514	2.2	
165	Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9572-9572	2.2	
164	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolmmunology</i> , 2016 , 5, e1238557	7.2	89
163	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
162	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). <i>Annals of Oncology</i> , 2016 , 27, vi386	10.3	5
161	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolmmunology</i> , 2016 , 5, e1201625	7.2	16
160	Neoantigen landscape dynamics during human melanoma-T cell interactions. <i>Nature</i> , 2016 , 536, 91-5	50.4	285
159	Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. <i>World Journal of Urology</i> , 2016 , 34, 1067-72	4	13
158	Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 258.e7-258.e13	2.8	13

157	Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. <i>Annals of Oncology</i> , 2016 , 27, 1138-1142	10.3	59
156	The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3026-3026	2.2	3
155	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9505-9505	2.2	40
154	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9526-9526	2.2	2
153	Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9592-TPS9592	2.2	2
152	Time to targeted therapy after cytoreductive nephrectomy (CN) and surveillance in patients with synchronous unresectable metastases of renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 604-604	2.2	4
151	Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21011-e21011	2.2	
150	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21058-e21058	2.2	
149	A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4550-4550	2.2	
148	Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. <i>BMC Cancer</i> , 2016 , 16, 364	4.8	7
147	The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1307-12	2.9	22
146	BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. <i>Cell Reports</i> , 2016 , 16, 263-277	10.6	40
145	Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. <i>European Journal of Immunology</i> , 2016 , 46, 1351-60	6.1	23
144	Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial. <i>Clinical Skin Cancer</i> , 2016 , 1, 48-52		6
143	CANCER IMMUNOLOGY. The "cancer immunogram". <i>Science</i> , 2016 , 352, 658-60	33.3	463
142	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016 , 91, 267-273	3.6	9
141	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016 , 76, 32-40	4.2	11
140	NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2015 , 13, 32	8.5	67

139	Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1241-50	7.4	78
138	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 457-72	31.3	447
137	Toxicity patterns with immunomodulating antibodies and their combinations. <i>Seminars in Oncology</i> , 2015 , 42, 423-8	5.5	45
136	Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. <i>Molecular Oncology</i> , 2015 , 9, 1918-35	7.9	74
135	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. <i>Clinical Cancer Research</i> , 2015 , 21, 4251-3	12.9	1
134	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. <i>Molecular Therapy</i> , 2015 , 23, 1541-50	11.7	76
133	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015 , 42, 55-66		93
132	Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization. <i>Journal of Immunology</i> , 2015 , 195, 5285-95	5.3	44
131	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. <i>Nature Medicine</i> , 2015 , 21, 81-5	50.5	478
130	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. <i>EMBO Molecular Medicine</i> , 2015 , 7, 1104-18	12	100
129	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
128	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	40	926
127	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015 , 122, 1907-16	7.3	46
126	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA1-LBA1	2.2	18
125	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014 , 508, 118-22	50.4	550
124	Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2014 , 110, 2441-9	8.7	67
123	T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. <i>Science</i> , 2014 , 346, 101-5	33.3	342
122	Acquired and intrinsic resistance in cancer immunotherapy. <i>Molecular Oncology</i> , 2014 , 8, 1132-9	7.9	133

121	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195
120	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 449-58	7.4	207
119	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , 2014 , 15, 323-32	21.7	753
118	Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. <i>Cancer Immunology Research</i> , 2014 , 2, 538-46	12.5	26
117	Clinical Trial Design 2014 , 179-201		
116	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014 , 5, 5712	17.4	374
115	Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. <i>Human Gene Therapy Methods</i> , 2014 , 25, 277-87	4.9	38
114	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. <i>Science Translational Medicine</i> , 2014 , 6, 254ra128	17.5	281
113	Do targeted agents offer clinical benefit as presurgical therapy?. <i>World Journal of Urology</i> , 2014 , 32, 3-8	4	7
112	A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4604-TPS4604	2.2	2
111	Intradermal vaccination by DNA tattooing. <i>Methods in Molecular Biology</i> , 2014 , 1143, 131-40	1.4	10
110	Volume of metastases and survival in patients with synchronous metastatic renal cell carcinoma (mRCC) of intermediate Memorial Sloan Kettering Cancer Center (MSKCC) prognosis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15605-e15605	2.2	
109	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 305-12	14.4	12
108	Transposon leads to contamination of clinical pDNA vaccine. <i>Vaccine</i> , 2013 , 31, 3274-80	4.1	8
107	High-throughput identification of antigen-specific TCRs by TCR gene capture. <i>Nature Medicine</i> , 2013 , 19, 1534-41	50.5	127
106	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 616-22	2.2	607
105	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2013 , 13, 561	4.8	17
104	The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 2065-72	2.8	5

103	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta Oncologica</i> , 2013 , 52, 1786-8	3.2	60
102	Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. <i>Cancer Research</i> , 2013 , 73, 19-29	10.1	120
101	Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 97-105	1.6	39
100	A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2013 , 24, 2098-103	10.3	36
99	Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, e251-3	2.2	28
98	Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, e439-42	2.2	631
97	Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. <i>Clinical Nuclear Medicine</i> , 2013 , 38, e182-4	1.7	27
96	Validation of serum amyloid A as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. <i>European Urology</i> , 2012 , 62, 685-95	10.2	14
95	Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. <i>Vaccine</i> , 2012 , 30, 4259-66	4.1	10
94	Modest improvement in 20 years of kidney cancer care in the Netherlands. <i>European Journal of Cancer</i> , 2012 , 48, 1822-30	7.5	6
93	Targeting dendritic cells with antigen via dendritic cell-associated promoters. <i>Cancer Gene Therapy</i> , 2012 , 19, 303-11	5.4	12
92	Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19739-44	11.5	186
91	Behavior and function of tissue-resident memory T cells. <i>Advances in Immunology</i> , 2012 , 114, 203-16	5.6	35
90	Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. <i>Human Gene Therapy</i> , 2012 , 23, 1301-12	4.8	26
89	Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. <i>International Journal of Cancer</i> , 2012 , 131, E484-93	7.5	13
88	Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. <i>Journal of Clinical Oncology</i> , 2012 , 30, e7-e10	2.2	101
87	TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. <i>Oncolimmunology</i> , 2012 , 1, 409-418	7.2	139
86	DNA vaccines and intradermal vaccination by DNA tattooing. <i>Current Topics in Microbiology and Immunology</i> , 2012 , 351, 221-50	3.3	23

85	Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4611-4611	2.2	1
84	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
83	Cancer immunotherapy--revisited. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 591-600	64.1	282
82	A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. <i>Urology</i> , 2011 , 78, 832-7	1.6	26
81	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
80	Tilting the AXIS towards therapeutic limits in renal cancer. <i>Lancet, The</i> , 2011 , 378, 1898-900	40	8
79	Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2011 , 11, 505	4.8	24
78	The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. <i>European Urology</i> , 2011 , 60, 448-54	10.2	88
77	Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 953-63	7.4	62
76	Combination of targeted therapy and immunotherapy in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1359-71	7.4	36
75	Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. <i>International Journal of Cancer</i> , 2011 , 129, 397-406	7.5	29
74	The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2011 , 22, 1041-1047	10.3	72
73	T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. <i>Clinical Cancer Research</i> , 2011 , 17, 5736-47	12.9	32
72	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. <i>Clinical Cancer Research</i> , 2011 , 17, 620-9	12.9	130
71	A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). <i>Acta Oncologica</i> , 2011 , 50, 121-6	3.2	29
70	Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. <i>Clinical and Experimental Immunology</i> , 2010 , 162, 447-59	6.2	2
69	Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>British Journal of Cancer</i> , 2010 , 102, 803-9	8.7	135
68	Microbead-assisted retroviral transduction for clinical application. <i>Human Gene Therapy</i> , 2010 , 21, 1335-42	4	4

67	Re: Surgical resection of renal cell carcinoma after targeted therapy. A. A. Thomas, B. I. Rini, A. J. Stephenson, J. A. Garcia, A. Fergany, V. Krishnamurthi, A. C. Novick, I. S. Gill, E. A. Klein, M. Zhou and S. C. Campbell <i>J Urol</i> 2009; 182: 881-886. <i>Journal of Urology</i> , 2010 , 183, 1646-7; author reply 1647	2.5	
66	Synthetic vehicles for DNA vaccination. <i>Journal of Drug Targeting</i> , 2010 , 18, 1-14	5.4	24
65	Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. <i>Nature Medicine</i> , 2010 , 16, 565-70, 1p following 570	50.5	313
64	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
63	Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. <i>Acta Oncologica</i> , 2010 , 49, 520-3	3.2	34
62	DNA vaccination in oncology: current status, opportunities and perspectives. <i>Current Clinical Pharmacology</i> , 2010 , 5, 218-25	2.5	3
61	Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation. <i>AAPS PharmSciTech</i> , 2010 , 11, 344-50	3.9	20
60	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1173-83	7.4	44
59	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. <i>Journal of Controlled Release</i> , 2010 , 141, 234-40	11.7	61
58	Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?. <i>International Journal of Pharmaceutics</i> , 2010 , 390, 32-6	6.5	8
57	Targeted therapy for renal cell cancer: current perspectives. <i>Discovery Medicine</i> , 2010 , 10, 394-405	2.5	28
56	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4406-12	2.2	161
55	Optimization of intradermal vaccination by DNA tattooing in human skin. <i>Human Gene Therapy</i> , 2009 , 20, 181-9	4.8	52
54	DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisomers. <i>Journal of Controlled Release</i> , 2009 , 139, 153-9	11.7	22
53	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. <i>Angiogenesis</i> , 2009 , 12, 69-79	10.6	51
52	Preclinical development of T cell receptor gene therapy. <i>Current Opinion in Immunology</i> , 2009 , 21, 209-14	7.8	42
51	Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009 , 49, 282-8	3.5	14
50	Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. <i>World Journal of Urology</i> , 2009 , 27, 533-9	4	54

49	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. <i>Nature Methods</i> , 2009 , 6, 520-6	21.6	236
48	Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2009 , 101, 1224-1224	8.7	0
47	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology, The</i> , 2009 , 10, 757-63	21.7	478
46	Immunotherapeutic strategies: the melanoma example. <i>Immunotherapy</i> , 2009 , 1, 679-90	3.8	9
45	Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2008 , 99, 259-65	8.7	98
44	Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. <i>Vaccine</i> , 2008 , 26, 3346-51	4.1	37
43	GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 70, 429-38	5.7	40
42	Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. <i>Clinical Cancer Research</i> , 2008 , 14, 5884-92	12.9	115
41	Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis. <i>Urologia Internationalis</i> , 2008 , 80, 367-71	1.9	10
40	Long-term functionality of TCR-transduced T cells in vivo. <i>Journal of Immunology</i> , 2008 , 180, 6536-43	5.3	18
39	An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. <i>Journal of Immunology</i> , 2008 , 180, 6365-73	5.3	29
38	Requirements for effective antitumor responses of TCR transduced T cells. <i>Journal of Immunology</i> , 2008 , 181, 5128-36	5.3	49
37	Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. <i>Cancer Research</i> , 2008 , 68, 2455-62	10.1	4
36	Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. <i>Cancer Research</i> , 2008 , 68, 8446-55	10.1	55
35	Sunitinib for treatment of advanced renal cell cancer: primary tumor response. <i>Clinical Cancer Research</i> , 2008 , 14, 2431-6	12.9	137
34	Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. <i>Clinical Cancer Research</i> , 2008 , 14, 4532-42	12.9	106
33	T-cell receptor gene therapy of established tumors in a murine melanoma model. <i>Journal of Immunotherapy</i> , 2008 , 31, 1-6	5	54
32	Optimization of intradermal vaccination by DNA tattooing in human skin. <i>Human Gene Therapy</i> , 2008 , 20, 081125111040089	4.8	18

31	Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. <i>BMC Biotechnology</i> , 2007 , 7, 2	3.5	21
30	Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. <i>Laboratory Investigation</i> , 2007 , 87, 161-72	5.9	39
29	In vivo antigen stability affects DNA vaccine immunogenicity. <i>Journal of Immunology</i> , 2007 , 179, 2126-33	5.3	34
28	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. <i>Blood</i> , 2007 , 110, 3564-72	7.2	87
27	Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. <i>Journal of Immunotherapy</i> , 2007 , 30, 234-9	5	19
26	Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 451-8	7.4	111
25	In situ visualization of antigen-specific T cells in cryopreserved human tissues. <i>Journal of Immunological Methods</i> , 2006 , 310, 78-85	2.5	11
24	Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. <i>Clinical Cancer Research</i> , 2006 , 12, 2826-33	12.9	32
23	Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. <i>Journal of Immunology</i> , 2006 , 176, 5213-22	5.3	72
22	Targeting self-antigens through allogeneic TCR gene transfer. <i>Blood</i> , 2006 , 108, 870-7	2.2	51
21	Design and use of conditional MHC class I ligands. <i>Nature Medicine</i> , 2006 , 12, 246-51	50.5	262
20	Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. <i>European Journal of Cancer</i> , 2005 , 41, 386-92	7.5	39
19	A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. <i>Nature Medicine</i> , 2005 , 11, 899-904	50.5	138
18	A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 713-9	7.4	20
17	Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 926-31	7.4	14
16	Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. <i>Cancer Research</i> , 2004 , 64, 2153-61	10.1	38
15	On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. <i>Clinical Cancer Research</i> , 2004 , 10, 4754-60	12.9	45
14	Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 2657-62	11.5	121

13	Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers 2003 , 111-130		
12	In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. <i>Nature Medicine</i> , 2002 , 8, 410-4	50.5	242
11	Optimizing the efficacy of epitope-directed DNA vaccination. <i>Journal of Immunology</i> , 2002 , 168, 4998-5004	36	
10	A redundant role of the CD3 gamma-immunoreceptor tyrosine-based activation motif in mature T cell function. <i>Journal of Immunology</i> , 2001 , 166, 2576-88	5.3	31
9	Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. <i>European Journal of Immunology</i> , 2000 , 30, 1297-307	6.1	28
8	Tracing and characterization of the low-avidity self-specific T cell repertoire. <i>European Journal of Immunology</i> , 2000 , 30, 1458-68	6.1	55
7	In situ detection of virus- and tumor-specific T-cell immunity. <i>Nature Medicine</i> , 2000 , 6, 1056-60	50.5	74
6	Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. <i>Journal of Experimental Medicine</i> , 1999 , 190, 1319-28	16.6	104
5	Systemic T cell expansion during localized viral infection. <i>European Journal of Immunology</i> , 1999 , 29, 1168-74	73	
4	Clonal dominance and selection for similar complementarity determining region 3 motifs among T lymphocytes responding to the HLA-DR3-associated Mycobacterium leprae heat shock protein 65-kd peptide 3-13. <i>Human Immunology</i> , 1995 , 44, 220-7	2.3	13
3	Regulation of mycobacterial heat-shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. <i>Immunological Reviews</i> , 1991 , 121, 171-91	11.3	56
2	HLA class-II-restricted Mycobacterium leprae-reactive T-cell clones from leprosy patients established with a minimal requirement for autologous mononuclear cells. <i>Scandinavian Journal of Immunology</i> , 1986 , 23, 101-8	3.4	24
1	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells		2